Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Depression
Piedmont Triad, N.C., biotech news/Targacept Initiates Phase 2 Study of TC-5214 in Patients with Resistant Hypertension
May 30th, 2009
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, announced the initiation of a Phase 2 exploratory study of TC-5214, a nicotinic channel blocker, as an augmentation therapy for resistant hypertension. TC-5214 is also being studied in an ongoing Phase 2b clinical trial as an augmentation therapy for major depressive disorder. "We believe the unique profile of TC-5214 makes it a promising product candidate as an augmentation therapy to existing medications to help address the unmet need for patients with resistant hypertension," said J. Donald deBethizy, Ph.D., President and Chief...
Source: Law & Health Weekly (2009-05-30)
|
